iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/22854664
Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;8(8):1156-60.
doi: 10.4161/hv.20740. Epub 2012 Aug 1.

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer

Michael G Hanna Jr  1
Affiliations
Review

Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer

Michael G Hanna Jr. Hum Vaccin Immunother. 2012 Aug.

Abstract

At the cellular level it is clear that cancer is a genetic disease arising as a clone that expands and grows in an unregulated manner. While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years has the magnitude and diversity of these mutations been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. Target therapies require targets. In this case the targets are tumor specific or associated antigens, the proteins expressed from these somatic cell mutations. While the immunotherapeutic approach to eliminating cancer was launched with the assumption that cancer cells were homogeneous, the recent genomic understanding of tumor cells indicates that there is both inter- and intra-tumoral heterogeneity. This presentation will discuss the consequences of this new knowledge of tumor cell biology to the immunotherapeutic approach to treating cancer.

PubMed Disclaimer

Figures

None
Figure 1. Study—recurrence free survival in stage II patients.
None
Figure 2. 8701 Study—overall survival in Stage II patients.
None
Figure 3. 8701 Study—recurrence free interval in Stage II patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Byers VS, Johnston JO. Antigenic differences among osteogenic sarcoma tumor cells taken from different locations in human tumors. Cancer Res. 1977;37:3173–83. - PubMed
    1. Pimm MV, Baldwin RW. Antigenic differences between primary methylcholanthrene-induced rat sarcomas and post-surgical recurrences. Int J Cancer. 1977;20:37–43. doi: 10.1002/ijc.2910200108. - DOI - PubMed
    1. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977;197:893–5. doi: 10.1126/science.887927. - DOI - PubMed
    1. Poste G, Doll J, Fidler IJ. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci U S A. 1981;78:6226–30. doi: 10.1073/pnas.78.10.6226. - DOI - PMC - PubMed
    1. Hanna MG Jr., Peters LC, Hoover HC Jr. Immunotherapy by Active Specific Immunization: Basic Principles and Preclinical Studies. Chapter 25, Biologic Therapy of Cancer Principles and Preclinical Studies. Biologic Therapy of Cancer Principles and Practice. Ed. DeVita VT, Hellman S, Rosenberg, SR, p 651, 1991, J. P. Lippincott, Co.

MeSH terms